Open Access<p>Antitumor Activity of Cabazitaxel and MSC-TRAIL Derived Extracellular Vesicles in Drug-Resistant Oral Squamous Cell Carcinoma</p>
Author(s) -
Yongle Qiu,
Jirun Sun,
Junping Qiu,
Guoling Chen,
Xiao Wang,
Yaxu Mu,
Kunshan Li,
Wenjing Wang
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s277324
Subject(s) - pi3k/akt/mtor pathway , apoptosis , exosome , flow cytometry , cancer research , microvesicles , protein kinase b , chemistry , in vivo , in vitro , microbiology and biotechnology , biology , biochemistry , microrna , gene
TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) can induce apoptosis in a variety of cancer cells. However, drug resistance of tumor and short half-life seriously affects its clinical targeted therapy. Cabazitaxel (CTX) is a taxane drug, which can induce apoptosis or autophagy by inhibiting the phosphorylation of PI3K/Akt/mTOR and sensitive to some drug-resistant tumors. Therefore, we explored the possibility of developing a mesenchymal stem cell-derived exosomes (MSC-EXO) vector for oral squamous cell carcinoma (OSCC) to deliver CTX/TRAIL combinations.